Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants
- John Fullarton; Ian Keary; Bosco Paes; Jean-Eric Tarride; Xavier Carbonell-Estrany; Barry Rodgers-Gray
Access Resources
About
This letter to the editor describes the impact of using nirsevimab to prevent RSV in US infants. It highlights issues with cost data and assumptions used in the study, which could affect its usefulness for decision-makers. The authors note that important indirect costs, like parents missing work due to sick children, were not included. They suggest involving more experts in future studies for better accuracy and relevance. The article emphasizes the need for clear information on costs and methods so others can replicate or adapt the findings to different healthcare systems.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.